Premium
Clinical outcomes after peripheral blood stem cell donation by related donors: a Dutch single‐center cohort study
Author(s) -
WiersumOsselton Johanna C.,
van Walraven Suzanna M.,
Bank Ivan,
Lenselink A. Mariëtte,
Fibbe Willem E.,
van der Bom Johanna G.,
Brand Anneke
Publication year - 2013
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/j.1537-2995.2012.03676.x
Subject(s) - medicine , incidence (geometry) , donation , confidence interval , cohort , population , single center , adverse effect , pediatrics , physics , environmental health , optics , economics , economic growth
BACKGROUND: Relatives donating peripheral blood stem cells (PBSCs) may be accepted for donation on less strict criteria than unrelated donors. We evaluated the occurrence of adverse events during procedure and follow‐up, with a special focus on donors who would have been deferred as unrelated donors. STUDY DESIGN AND METHODS: All 268 related PBSC donors at our center (1996‐2006) were included. Data were retrospectively collected from medical reports and standard follow‐up. Health questionnaires were sent from 2007. Medical outcomes of donors, deferrable or eligible according to international criteria for unrelated donation, were compared. RESULTS: Forty donors (15%) would have been deferred for unrelated donation. Short‐term adverse events occurred in 2% of procedures. Questionnaires were returned by 162 (60%) donors on average 7.5 years after donation, bringing total person‐years of follow‐up to 1278 (177 in deferrable donors). Nine malignancies and 14 cardiovascular events were reported. The incidence rate of cardiovascular events in eligible donors was 6.5 (95% confidence interval [CI], 2.5‐12.3) per 1000 person‐years compared to 44.9 (95% CI, 17.4‐85.2) in deferrable donors; incidence rates of malignancies were 4.6 (1.4‐9.6) and 24.0 (6.0‐53.9) per 1000 person‐years, respectively, in eligible and deferrable donors. All incidence rates were within the range of age‐ and sex‐matched general population. No autoimmune disorders were reported. CONCLUSION: In both the eligible and the deferrable related donors treated with granulocyte–colony‐stimulating factor there are few short‐term and long‐term problems. The occurrence of post‐PBSC cardiovascular events and malignant disease in related donors appears to be within the range of the general population.